Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000549714 | SCV000653704 | likely benign | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5 | 2024-12-16 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002476193 | SCV002803004 | likely benign | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5; Thyrotoxic periodic paralysis, susceptibility to, 1 | 2021-07-21 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003223654 | SCV003919222 | uncertain significance | not provided | 2022-10-21 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Breakthrough Genomics, |
RCV003223654 | SCV005261051 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Ambry Genetics | RCV004965570 | SCV005546300 | uncertain significance | Inborn genetic diseases | 2024-06-25 | criteria provided, single submitter | clinical testing | The c.3890G>A (p.G1297E) alteration is located in exon 32 (coding exon 32) of the CACNA1S gene. This alteration results from a G to A substitution at nucleotide position 3890, causing the glycine (G) at amino acid position 1297 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |